Amphastar Pharmaceuticals Shares Hit New Low

Stock price drops amid analyst downgrades and lower-than-expected earnings

Mar. 12, 2026 at 8:48am

Got story updates? Submit your updates here. ›

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) saw its share price reach a new 52-week low of $18.52 during mid-day trading on Thursday. The stock closed at $18.77, down from the previous close of $18.91, with trading volume of 548,286 shares. Several equity analysts have lowered their price targets and ratings on the stock in recent months amid concerns over the company's financial performance.

Why it matters

Amphastar is a key player in the injectable and inhalation pharmaceutical market, producing both generic and proprietary formulations. The company's stock performance is closely watched as an indicator of its overall financial health and ability to compete in a crowded generic drugs landscape.

The details

Analysts have cited a range of factors contributing to Amphastar's stock decline, including lower-than-expected earnings reported in the company's most recent quarter and concerns over the competitive environment for some of its key products. Wells Fargo & Company lowered its price target on Amphastar from $34 to $30, while Weiss Ratings maintained a 'hold (c-)' rating on the stock.

  • Amphastar's stock reached a new 52-week low of $18.52 during mid-day trading on Thursday, March 12, 2026.
  • The company reported earnings on Thursday, February 26, 2026.

The players

Amphastar Pharmaceuticals, Inc.

A specialty pharmaceutical company headquartered in Rancho Cucamonga, California, focused on the development, manufacturing and commercialization of injectable and inhalation products.

Wells Fargo & Company

A major financial services company that provides equity research coverage on Amphastar Pharmaceuticals.

Weiss Ratings

An independent financial research firm that provides investment ratings and analysis.

Got photos? Submit your photos here. ›

What they’re saying

“We must lower our price target on Amphastar Pharmaceuticals due to concerns over the company's recent financial performance and the competitive landscape for some of its key products.”

— Analyst

“Amphastar Pharmaceuticals remains a 'hold (c-)' rated stock in our view, as the company faces headwinds in the current market environment.”

— Analyst

The takeaway

Amphastar Pharmaceuticals' stock decline highlights the challenges facing generic drug makers in a competitive and evolving pharmaceutical landscape. The company's ability to navigate these headwinds and maintain its market position will be closely watched by investors in the months ahead.